Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic engineering could salvage once-promising anti-cancer agents

11.06.2002


A group of anti-cancer agents that once produced dismal results in clinical trials could once again be a promising tool in fighting the deadly disease, thanks to research by a team of chemists at the University of Washington and in Germany.



The agents, called maytansinoids, were first discovered in the 1970s when scientists looked for tumor inhibitors in a rare Ethiopian plant. The same group of maytansinoids was later isolated from a new bacteria species. The compounds held great promise because of their exceptional potency, and early tests indicated they were effective against some tumors and leukemia lines.

But the compounds were difficult to come by in quantities large enough to manufacture drugs and, when potential treatments were developed, they proved too strong when tested in clinical trials.


"These compounds were too potent. They were toxic to patients," said Tin-Wein Yu, a UW research assistant professor of chemistry. "We thought if we could modify the chemical structure to make the agents more appropriate for cancer patients, that would be beneficial. And we could use the same strategy to ease the side effects."

UW researchers headed by Heinz Floss, an emeritus chemistry professor, teamed with researchers from Rheinische Wilhems-Universität in Bonn, Germany, to develop ways of modifying genes that create maytansinoids and then produce cancer treatments that are more effective against tumors and better tolerated by patients.

Their efforts essentially relied on using the modified genes to produce the anti-cancer agent. The first step was to locate the genes that control maytansinoid formation and clone them. They first gained access to genes that control maytansinoid production, then altered the maytansinoid structure at the genetic level.

"If you can manipulate the production genes, it makes the process much easier," said Yu, who is the lead author of a paper describing the work in the June 11 issue of the Proceedings of the National Academies of Science.

To clone the genes, the researchers snipped the genome of the bacteria (Actinosynnema pretiosum) into small bits to create a genomic library. They used a gene that already had been cloned from another microorganism (Amycolatopsis mediterranei) as a reference to screen the library and find the genes needed for maytansinoid construction. Having access to the genes that control the formation of maytansinoids allows scientists to manipulate the structure of the anti-cancer agent at the DNA level.

The work, for which the UW has applied for a patent, allows for a detailed analysis of maytansinoid formation at both the genetic and biochemical levels. It also sets the stage to modify maytansinoids through genetic engineering, so they are less toxic to humans, are more effective against cancer and bond easily with delivery agents.

Several companies are in discussions about the possibility of using the research to combine maytansinoids with antibodies that target tumors. The antibodies would search out specific cancer antigens attach only to cancer cells, Yu said. The maytansinoids then can enter the cancer cells and destroy them without damaging surrounding healthy tissue.

"It is a warhead strategy," he said.

The work has provided researchers with a number of options other than simply deciphering the biosynthesis of pre-existing compounds, Yu said. Manipulating the structure, he said, ultimately could lead to development of more effective cancer drugs.



The research was funded by grants from the National Institutes of Health, Deutsche Forschungsgemeinschaft (Germany’s central public funding organization for academic research), the Fonds der Chemischen Industrie in Germany and the North Atlantic Treaty Organization.

For more information, contact Yu at (206) 543-3791 or yu@u.washington.edu

Vince Stricherz | EurekAlert

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>